Maze Therapeutics Files 8-K on Operations, Officer Changes

TL;DR

**Maze Therapeutics just dropped an 8-K with operational results and officer changes, so dig into the details!**

AI Summary

Maze Therapeutics, Inc. filed an 8-K on March 25, 2026, reporting on its results of operations and financial condition (Item 2.02), changes in directors or officers and their compensation (Item 5.02), and Regulation FD Disclosure (Item 7.01). This filing indicates significant operational and leadership updates, which could signal strategic shifts or financial performance changes. Investors should pay close attention to the details within these items, particularly regarding any new executive appointments or financial results, as they directly impact the company's future direction and potential stock performance.

Why It Matters

This filing signals potential strategic shifts or financial performance updates at Maze Therapeutics, which could impact its stock valuation and future prospects. Investors need to review the specific details of the operational results and leadership changes to assess the company's health and direction.

Risk Assessment

Risk Level: medium — The filing indicates changes in operations and leadership, which can introduce both opportunities and risks depending on the specifics not fully detailed in this summary.

Analyst Insight

A smart investor would closely monitor Maze Therapeutics' upcoming announcements or detailed exhibits related to this 8-K, particularly those concerning financial performance and any new executive appointments or departures, to understand the full implications for the company's future.

Key Players & Entities

• Maze Therapeutics, Inc. (company) — Filer of the 8-K
• 0001842295 (company) — CIK of Maze Therapeutics, Inc.
• 2026-03-25 (date) — Filing Date
• 2026-03-24 (date) — Period of Report

Forward-Looking Statements

• Maze Therapeutics will announce specific financial results and executive changes in subsequent detailed filings or press releases. (Maze Therapeutics, Inc.) — high confidence, target: 2026-04-30
• The stock price of Maze Therapeutics may experience volatility as investors react to the undisclosed details of the operational results and leadership changes. (Maze Therapeutics, Inc.) — medium confidence, target: 2026-04-01

FAQ

Key Financial Figures

• $0.001 — h registered Common Stock - par value $0.001 per share MAZE The Nasdaq Stock Mar
• $40,000 — will receive a pro rata portion of the $40,000 annual retainer for service as a direct
• $750,000 — ng Standards Codification Topic 718) of $750,000 as of the Appointment Date, with 1/36th

Filing Documents

• maze-20260324.htm (8-K) — 52KB
• maze-ex99_1.htm (EX-99.1) — 194KB
• maze-ex99_2.htm (EX-99.2) — 27KB
• img92905542_0.jpg (GRAPHIC) — 11KB
• img93829063_0.jpg (GRAPHIC) — 19KB
• 0001193125-26-122774.txt ( ) — 439KB
• maze-20260324.xsd (EX-101.SCH) — 24KB
• maze-20260324_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On March 25, 2026, Maze Therapeutics Inc. (the "Company") issued a press release reporting its financial results for the fourth quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the date hereof, except as expressly set forth by reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 24, 2026, the Board of Directors (the "Board") of the Company appointed Neil Kumar as a Class I director, effective March 27, 2026 (the "Appointment Date"). Dr. Kumar is currently a co-founder and the Chief Executive Officer of BridgeBio Pharma, Inc., where he has worked since April 2015. Dr. Kumar has also served as the Chief Executive Officer of Eidos Therapeutics, Inc., a clinical-stage biopharmaceutical company, and a member of Eidos Therapeutics' board of directors since March 2016. Dr. Kumar served as Chief Executive Officer and President of BridgeBio Oncology Therapeutics, Inc. from August 2016 to April 2024. Dr. Kumar served as the interim vice president of business development at MyoKardia, Inc. (acquired by Bristol Myers Squibb), a clinical-stage biopharmaceutical company, from 2012 to 2014. Prior to that, Dr. Kumar served as a principal at Third Rock Ventures, a venture capital f

01 Regulation FD

Item 7.01 Regulation FD. On March 25, 2026, the Company issued a press release announcing topline data from its Phase 2 clinical trial of MZE829 in patients with APOL1-mediated kidney disease. The full text of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act, nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the date hereof, except as expressly set forth by reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 99.2 Press Release announcing financial results, dated March 25, 2026. Press Release announcing MZE829 data, dated March 25, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 25, 2026 By: /s/ Courtney Phillips Courtney Phillips General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR